The precise diagnosis of an immunodeficiency is sometimes difficult to assess, especially due 2 to the large spectrum of phenotypic variation reported among patients. Common variable 3 immunodeficiency disorders (CVID) do not have, for a large part, an identified genetic cause. 4
Introduction
Total RNA was extracted from PHA T-cell blast and EBV-transformed B-cells with 1 TRIzol (Invitrogen). The mRNA was reverse-transcribed with oligo-dT primers and 2
SuperScriptIII reverse transcriptase (Invitrogen), to obtain cDNA. 3 Cloning of the amplified cDNA 4
The PCR products obtained after RNA extraction and cDNA amplification were 5 inserted into the TOPOÒ TA cloning vector (Invitrogen) and sequenced. 6
Flow cytometry analysis of BTK expression 7
Intracellular BTK staining was performed on thawed PBMC with the Fix and Perm® 8 kit (Caltag), used according to the manufacturer's instructions. PBMC were first stained with 9 FITC-conjugated anti-CD14 (IgG2a; Immunotech), PerCP-Cyanine5.5-conjugated anti-CD45 10 (IgG1; BD Biosciences) and APC-conjugated anti-CD19 (IgG1; BD Biosciences) for 15 11 minutes at room temperature. The cells were fixed, washed and permeabilized and Fc receptors 12
were blocked by incubation with human serum for 15 minutes at room temperature. 
CD40LG mutation screening 2
Four patients with a primary HIGM diagnosis were included in our cohort for genetic 3 screening. Of those, only 3 presented a mutation in CD40LG: 228_231delAAGA, 409+1G>A 4 and 410-2A>G ( Figure 1A ). These mutations were associated with an absence of CD40L cell 5 surface detection on activated T-cell (see table 2 ). The fourth patient with an HIGM diagnosis 6 may carry a mutation in another HIGM-causing gene (e.g. AICDA, CD40) [33, 34] and as such 7
should be screened for it. We did not identify any CD40LG mutation in any other patient of the 8 cohort. 9
SH2D1A mutation screening 10
No patient included in our cohort were initially diagnosed with XLP. After identifying 11 a first patient initially diagnosed with CVID but carrying a SH2D1A mutation (patient S1) in 12 the first 150 patients, we expanded our SH2D1A screening to 80 additional individuals and 13 identified a second CVID patient with a SH2D1A mutation (patient S2, table 3 and figure 1B). 14 Patient S1 was mutated in intron 2: 201+3A>G. We identified and sequenced two 15 splicing mRNA variants in activated T-cells by RT-PCR: a first variant where exon 2 were 16 spliced out (cDNA fragment of 323bp) and a second variant where exon 2 and a portion of exon 17 3 were spliced out (cDNA fragment of 268bp). We did not detect SAP protein expression in 18 activated T-cells protein extracts using immunoblot technique (Figure 2) . Patient S2 carried a 19 E67G coding mutation in exon 2 that was associated with an absence of SAP protein on the 20 immunoblot performed with activated T-cells protein extract (Figure 2) . 21
The clinical presentation of of these 2 patients was as followed. Patient S1 first diagnosis was 22 pediatric CVID at eight years of age after detection of hypogammaglobulinemia during 23 bacterial pneumonia. He also suffered from severe infectious mononucleosis at six years of age. 24
The patient was treated with gammaglobulins, administered intramuscularly for the first 10 1 years, and then intravenously. Patient S1 had 4% circulating B-cells including 87% naive 2 (CD27-IgM+), 3% switched memory (CD27+IgM-) and 7% CD27+IgM+ B-cells (Table 3) . 3
He presented a family history suggestive of X-linked disease, indeed, his older brother died 4 with a refractory digestive EBV-driven B large cell lymphoma in the course of an otherwise 5 unremarkable CVID, without previous severe EBV primo-infection. Patient S2 was diagnosed 6 with CVID at the age of 40 based on the detection of profound hypogammaglobulinemia after 7 severe bacterial pneumonia without familial history of X-linked disease. He denied suffering 8 severe EBV primary infection, despite chronic positive plasma circulating EBV viral load. The 9 patient had 4% circulating B-cells including 19% naive (CD27-IgM+), 57% switched memory 10 (CD27+IgM-) and 15% CD27+IgM+ B-cells (Table 3) . 11
BTK mutation screening 12
In our cohort, 7% of patients presented with an initial diagnosis of XLA ( Strikingly, we found a BTK mutation in 5 patients (B21-B25) with a primary diagnosis of CVID 21 or IgG subclass deficiency (Table 4 , boxes in Figure 1C ). Overall, we described 20 different 22 mutations in 22 patients, including 5 novel mutations while the others were previously reported 23 in the BTK database (https://databases.lovd.nl/shared/genes/BTK) [37] . 24 We observed a phenotypic variability in patients carrying BTK mutations despite 1 showing all less than 1% B-cells; indeed, while a majority of patients presented their first 2 symptoms at early age in infancy some were described at later age (up to 18 years old for B22, 3 see Figure 3 ). As expected, BTK protein was 12 undetectable in all 13 patients' monocytes with a primary diagnosis of XLA, as illustrated with 13 patient B14 on Figure 3A . When considering the 3 patients with a primary diagnosis of XLA 14 but without identified BTK mutation, we detected a lower ∆MFI in 2 patients (B18 and B19, 15 Figure 3B ) and a ∆MFI in the normal range for the B20 patient ( Figure 3B ). 16
Finally, we measured BTK expression in 4 out of 5 patients carrying a BTK mutation 17 but without a primary diagnosis of XLA, as we could not measure BTK expression for patient 18 B24. However, this patient carried the same M630V mutation as for the XLA B5 patient, so we 19 can only extrapolate that he might also present an undetectable BTK expression (Table 4) . BTK 20 expression was undetectable in patients B22 and B25 monocytes, who were primarily 21 diagnosed with CVID and IgG subclass deficiency, respectively (Table 4, Figure 3C ). Patients 22 B21 and B23 showed a decreased but detectable BTK expression in monocytes ( Figure 3C ), in 23 normal range for B21 (∆MFI=80) and just below for B23 (∆MFI=69). R28H mutation is 24 described in multiple studies as responsible for the XLA phenotype (Table 4) , moreover, it is 25 reported as pathogenic in the ClinVar database 1 (https://www.ncbi.nlm.nih.gov/clinvar/variation/11348/). These suggest strongly that R28H is 2 responsible of patient B21 phenotype. G164D coding mutation is predicted by the CADD 3 bioinformatics tool [38] to be damaging for the protein function (score: 29.1). This mutation is 4 not described in populations databases such as the 1000 Genomes project [31] . These data are 5 not sufficient to describe G164D as responsible of the disease, additional family testing would 6 permit to settle this down. Altogether, these results suggest an alternative pathophysiological 7 mechanism to the absence of detectable BTK protein: lower level of BTK may indicate a 8 dysfunction of the BTK signaling pathway that could consequently alter the development of B-9 cells and promote hypogammaglobulinemia. 10 
11

Discussion 1
We sequenced three genes (CD40LG, SH2D1A, BTK) located on the X chromosome in 2 male patients with primary humoral deficiencies from the French national DEFI cohort ( Figure  3   S1 ). Deleterious mutations in these genes are responsible of profound defects in 4 immunoglobulin production, are usually diagnosed in children and associated with specific 5 phenotypes. We intentionally did not restrict patients' selection to any particular clinical or 6 biological phenotypes as we intended to identify mutations outside of a commonly recognized 7 clinical presentation. We demonstrated that the systematic screening of these genes is useful to 8 confirm and/or reclassify immune defects diagnosis in adults with humoral primary 9 immunodeficiency. 10 CD40LG genetic screening of 150 male patients did not reveal any mutation outside of 11 the classical clinical presentation of HIGM, indicating that the CD40LG mutations are 12 responsible for a very specific clinical and immunological phenotype that cannot be confused 13 with CVID or any other defects. One patient with a HIGM phenotype did not exhibit any 14 mutation in CD40LG; to further characterize this patient's disease, additional genetic analyses 15 should be performed for autosomal recessive HIGM genes such as AICDA, CD40 or UNG 16 [33, 34] . 17
Here, we characterized 2 patients primarily diagnosed as CVID but presenting a 18 SH2D1A mutation with an absence of SAP detection by immunoblot. XLP main feature is an 19 extreme susceptibility to EBV infection, and one of these 2 patients presented a severe 20 infectious mononucleosis at six years of age. However, the second one claimed he did not suffer 21 any severe EBV primary infection during his childhood and had no familial history of X-linked 22 disease. This indicates that, despite the low percentage of diagnosed patients (2 out of 145 if 23 we consider only CVID), the SH2D1A mutation knowledge is important in all male patients 24 diagnosed with CVID, whether or not they have a medical or familial history consistent with 25 severe EBV infection. Indeed, the XLP diagnosis significantly modifies the therapeutic and 1 follow-up options of the patients. 2
The systematic sequencing of BTK in 181 male patients confirmed the suspected XLA 3 diagnosis in 17/20 patients. Moreover, we identified 5 patients with a primary diagnosis of 4 CVID or IgG subclass deficiency carrying a mutation in the BTK gene. This misdiagnosis could 5 have several explanations: persistence of low levels but detectable IgG, IgA or IgM; insufficient 6 genealogic investigation to detect familial X-linked disease; onset of disease at adulthood; 7 absence of serious pulmonary complications. It emphasizes that all male patients with a 8 diagnosis of primary humoral immunodeficiency and with very low levels of circulating B-cells 9 (<1%), regardless of age at diagnosis, residual Ig concentration or familial history, should be 10 screened for BTK defects, either by FACS detection in monocytes or by direct sequencing of 11 the coding region. 12
The 3 patients referred to us with a diagnosis of XLA and in whom we could not identify 13 another BTK regulatory region not covered by the sequencing method we implemented. 21
Alternatively, other intracellular proteins in the B-cell lineage may be absent or defective in 22 these patients, accounting for the weak translation of BTK and the low level of BTK activity in 23 B-cell precursors. These patients may carry a mutation in genes responsible of autosomal 24 recessive agammaglobulinemia, and especially B20 considering his family history. Beyond 25 these previously identified genes, an agnostic screening using whole-exome or whole-genome 1 next-generation sequencing (NGS) might also reveal novel disease-causing genes. 2
With the rising of NGS technologies, the possibility of genetic screening has increased. 3
Our results advocate to include SH2D1A and BTK genes in newly developed targeted NGS 4 panel genetic testing for all primary immunodeficiency diagnosis including CVID or related 5 hypogammaglobulinemia. This is supported by the fact that such NGS panel are already in 6 place, they include SH2D1A and BTK but also other genes responsible of HIGM, XLP or XLA 7 diseases (e.g. CD40, PIK3R1, etc.). This will further help characterize monogenic forms of 8 CVID, which still count for less than 10% of patients [2], from polygenic forms of CVID. To 9 achieve deciphering the pathophysiology and help improve treatments of these complex forms 10 of CVID, and in addition with NGS, efforts should be combined and integrated from different 11 omics approaches such as epigenomics, proteomics and metabolomics [39, 40] . 12
In conclusion, our systematic genetic screening in a large cohort of adults with primary B5 and B24 do not belong to the same family. Patients B18 to B20 had an initial diagnosis of XLA based on phenotypic data, no mutation in 6 BTK were found. Newly described mutations are in bold. CVID or IgG subclass deficiency patients' mutations are boxed. Patients B21 to B25 7 had a primary diagnosis of humoral deficiency, 4 CVID and 1 IgG subclass deficiency. XL: X-linked; AR: autosomic recessive. 8 9 
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